Komipharm International Co., Ltd. (041960.KQ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	53.0B	52.5B	58.8B	42.6B	39.8B
Cost of Revenue	35.3B	36.6B	37.0B	30.0B	28.3B
Gross Profit	17.7B	15.9B	21.8B	12.7B	11.5B
Operating Expenses
R&D Expense	2.6B	3.5B	2.5B	5.9B	2.5B
SG&A Expense	7.4B	5.1B	5.2B	4.7B	4.3B
General & Admin Expense	1.4B	2.0B	1.9B	1.8B	1.6B
Selling & Marketing Expense	2.6B	3.1B	3.3B	2.9B	2.7B
Other Expenses	6.9B	7.2B	7.9B	8.3B	(2.9B)
Total Operating Expenses	16.7B	15.8B	15.6B	18.9B	15.3B
Cost and Expenses	52.0B	52.4B	52.6B	48.9B	43.6B
Operating Income (EBIT)	989.4M	86.6M	6.2B	(6.3B)	(3.8B)
Non-Operating
Interest Income	804.8M	834.8M	705.8M	678.4M	227.7M
Interest Expense	2.2B	2.6B	3.2B	2.6B	2.2B
Net Interest Income	(1.4B)	(1.8B)	(2.5B)	(1.9B)	(2.0B)
Other Non-Op Income/Expense	(4.3B)	(8.0B)	8.5B	533.6M	(3.7B)
Non-Operating Income (excl Interest)	3.2B	—	(11.7B)	(3.1B)	1.5B
EBT (Pre-Tax Income)	(3.3B)	(7.9B)	14.7B	(5.7B)	(7.5B)
Income Tax Expense	92.7M	92.7M	—	171.2M	—
Bottom Line
Net Income	(2.6B)	(7.2B)	13.1B	(4.0B)	(6.5B)
Earnings from Cont. Ops	(3.4B)	(8.0B)	14.7B	(5.9B)	(7.5B)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(2.6B)	(7.2B)	13.1B	(4.0B)	(6.5B)
Per Share
Basic EPS	(₩36)	(₩101)	₩188	(₩57)	(₩84)
Diluted EPS	(₩36)	(₩101)	₩188	(₩57)	(₩84)
Revenue Per Share	₩739	₩711	₩851	₩611	₩516
Shares
Basic Shares Outstanding	71.8M	73.8M	69.1M	69.8M	77.1M
Diluted Shares Outstanding	71.8M	73.8M	69.1M	69.8M	77.1M
Profitability Metrics
EBITDA	4.1B	2.9B	21.0B	341.7M	(1.4B)
D&A	2.8B	2.8B	3.1B	3.5B	3.8B
EBIT	1.2B	86.6M	17.9B	(3.2B)	(5.3B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026